Business Wire

Sisvel and RPX Conclude Licensing Agreement for Wi-Fi Standard Essential Patents

Del

Sisvel International S.A. (“Sisvel”) and RPX Corporation (“RPX”) today announced that they have entered into a multi-faceted agreement that provides a license to a subset of RPX clients covering more than 500 patents that make up the Sisvel Wi-Fi Joint Licensing Program. The Sisvel Wi-Fi Joint Licensing program is a solution designed to license standard essential patents (SEPs) for Wi-Fi enabled devices under fair, reasonable, and non-discriminatory terms and conditions (FRAND). In addition to the assets in the Sisvel Wi-Fi Licensing Program, Sisvel has also licensed the subset of RPX members to approximately 200 non-essential Wi-Fi assets, owned by Sisvel's subsidiary, Hera Wireless S.A.

In this transaction, Sisvel, a patent aggregator that brings together world-class patents from leading innovators, and RPX, an aggregator that constructs creative licensing solutions that enable its equally innovative clients to avoid or resolve patent disputes, came together to conclude a highly-efficient transaction that benefits the entire market. This transaction both provides adequate returns for innovators and simple, effective, and cost-efficient access to IP rights for the implementers. This is the first time that RPX has concluded a risk clearance patent transaction with a patent pool administrator.

The patents in the transaction are owned by Orange S.A., Fraunhofer IIS, Koninklijke KPN N.V., Columbia University, Hera Wireless S.A., Enact IP S.A., Aegis 11 S.A. In addition to the existing patent owners, Mitsubishi Electric Corp. joined this transaction and will now become a patent owner in the Sisvel Wi-Fi Joint Licensing Program.

This is a great example of how aggregators can find ways to work together to generate benefits for the whole technology ecosystem,” said Mattia Fogliacco, CEO of Sisvel. “Through this single transaction we are able to grant easy access to important technology and, at the same time, generate a fair return for the innovators. This one deal generates several benefits, including more clarity for the market and lower transaction costs.

Both RPX and Sisvel represent the interests of a wide group of clients from a variety of industries. This transaction clearly demonstrates the efficiencies of bringing companies together to create a powerful result that balances the interests of patent owners and companies that implement SEPs in their products,” said RPX Chief Executive Officer Dan McCurdy. “By acknowledging a shared interest and collectively combining knowledge and resources, companies achieve more effective results at a lower cost than would be possible individually.

About RPX
RPX Corporation is the leading provider of patent risk and discovery management solutions. Since its founding in 2008, RPX has introduced efficiency to the patent market by providing a rational alternative to litigation. The San Francisco-based company’s pioneering approach combines principal capital, deep patent expertise, and client contributions to generate enhanced patent buying power. By acquiring patents and patent rights, RPX helps to mitigate and manage patent risk for its growing client network.

As of December 31, 2018, RPX had invested over $2.4 billion to acquire more than 43,000 US and international patent assets and rights on behalf of approximately 320 clients in eight key sectors: automotive, consumer electronics and PCs, E-commerce and software, financial services, media content and distribution, mobile communications and devices, networking, and semiconductors.

About Sisvel
Sisvel International S.A. is the holding company of the Sisvel Group. Sisvel is a world leader in managing intellectual property and maximizing the value of patent rights. Founded in 1982, the Sisvel Group is global in scope and reach, with companies in Italy, the United States, Hong Kong, Japan, Germany, Luxembourg, and the United Kingdom, leveraging on professionals with technical, legal, and licensing expertise. Sisvel has a long history of managing successful patent portfolios including those related to the audio compression standards known as MP3 and MPEG Audio.

Sisvel currently operates patent pools and joint licensing programs for the DVB-T2, DVB-S2X, MCP, LTE/LTE-A, 3G, Wi-Fi and Recommendation Engine, together with its Sisvel Wireless licensing program and DSL licensing program.

For additional information, please visit: www.sisvel.com.

Contact information

Media
Sisvel Group
Giulia Dini
Communications Manager
Tel: +44 203 053 6930
giulia.dini@sisvel.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Rimini Street CEO Visits Seoul, Addresses Changing IT Mission19.3.2019 23:00:00 CETPressemelding

Rimini Street, Inc. (Nasdaq: RMNI), a global provider of enterprise software products and services, the leading third-party support provider for Oracle and SAP software products and a Salesforce partner, is committed to helping South Korean companies reduce ongoing IT operating costs and freeing up significant IT budget to invest in innovation, competitive advantage and growth, co-founder and CEO Seth A. Ravin explained during a press conference in Seoul. Mr. Ravin also highlighted continued strong and growing demand in Korea for the Company’s award-winning, ultra-responsive enterprise software support model, which is disrupting the $160 billion enterprise software maintenance market worldwide. As the 4th largest economy in Asia, and the 11th largest in the world, South Korea represents a large market opportunity for the Company. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190319005832/en/ Rimini Street CEO Visits Seoul,

SOTIO’s DCVAC/OvCa Significantly Improves Survival in Patients with Recurrent Ovarian Cancer19.3.2019 20:00:00 CETPressemelding

SOTIO, a biotechnology company owned by the PPF Group, presented results from SOV02, its Phase II clinical trial evaluating DCVAC/OvCa, an active cellular immunotherapy product, in patients with recurrent ovarian cancer at 2019 SGO’s 50 th Annual Meeting on Women's Cancer today. Final analysis of SOV02 shows that DCVAC/OvCa decreased the risk of death significantly compared to patients who did not receive DCVAC/OvCa. Clinical trial results were presented during today’s SGO 2019 Plenary Session by SOV02 principal investigator David Cibula, MD, PhD from General University Hospital in Prague (Czech Republic). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190319005837/en/ In the randomized, open label SOV02 clinical trial, patients with recurrent ovarian cancer received DCVAC/OvCa in combination with platinum-based chemotherapy. Compared to patients who did not receive DCVAC, it decreased the risk of death by 62%. The combinati

OCP Announces Date of Fourth Quarter and Full Year 2018 Earnings19.3.2019 19:00:00 CETPressemelding

OCP S.A. (“OCP” or the “Company”), a global leader in the fertilizer industry, will release its fourth quarter and full year 2018 results on Monday, March 25, 2019. The results will be available to holders of the Company’s bonds, qualified institutional buyers, securities analysts and market makers on the OCP Intralinks portal from 9:00 a.m. EDT, 2:00 p.m. Morocco time (GMT+1), and 1:00 p.m. London time (GMT). OCP senior management will host a conference call to discuss fourth quarter and full year 2018 results at 10:00 a.m. EDT, 3:00 p.m. Morocco time (GMT+1), and 2:00 p.m. London time (GMT) on Monday, March 25, 2019 for holders of the Company’s bonds, qualified institutional buyers, securities analysts and market makers. Eligible parties that have not already registered for access to the Intralinks portal may do so by contacting the Investor Relations Department by emailing g.laraki@ocpgroup.ma About OCP OCP is a global leader in the fertilizer industry, backed by almost a century’s

HCL and Xerox Expand Strategic Partnership to Accelerate Operational Transformation19.3.2019 16:51:00 CETPressemelding

HCL Technologies (HCL), a leading global technology company, announced that it signed a managed services agreement with Xerox (NYSE: XRX). Under the terms of the agreement, HCL will manage portions of Xerox’s shared services, including global administrative and support functions, including, among others, selected information technology and finance functions (excluding accounting). Leveraging HCL’s global scale and capabilities, Xerox will strategically evolve its shared services into process-first, technology-led digital operations. This seven-year agreement for an incremental $1.3 billion continues to build on the success of the Xerox-HCL relationship, which began in 2009 with product engineering and support services. Under that agreement, HCL currently manages aspects of Xerox’s mechanical, electrical and software engineering activities for printer and imaging product lines. Together, HCL and Xerox have delivered 215 U.S. patents and have created world-class R&D labs that are tightly

Abzena and Lipum AB Sign Integrated CMC Agreement to Produce a Novel Biologic for Autoimmune Inflammatory Diseases19.3.2019 15:18:00 CETPressemelding

Abzena, the global biologics gene to GMP partner research organization, announced it has signed an agreement to support an integrated CMC program with Lipum, a company developing treatments for chronic inflammatory diseases. Abzena will support Lipum’s anti-BSSL antibody IND program to help develop a novel therapeutic option for autoimmune inflammatory diseases, including juvenile idiopathic arthritis. The 18-month program includes: development of a research cell bank using Abzena’s proprietary cell line and ambr® 15 automated high throughput bioreactors, generation of master cell banks, scale up using an ambr® 250 during process development, followed by cGMP manufacturing in Sartorius 500 L single use stirred tank bioreactors for clinical material. The work will take place at Abzena’s sites in Cambridge, UK and San Diego, USA. Jonathan Goldman, CEO of Abzena, said: “Autoimmune inflammatory diseases such as juvenile idiopathic arthritis represent significant unmet medical need. We are

Guardsquare now Protects JavaScript Hybrid Mobile Apps19.3.2019 15:00:00 CETPressemelding

Guardsquare, the global reference in mobile protection, announces that DexGuard now protects JavaScript hybrid mobile applications for Android. The latest version of their state-of-the-art mobile security software, DexGuard 8.4, extends the existing code hardening capabilities with JavaScript obfuscation to provide superior protection to Android apps built with frameworks such as Cordova, Ionic and ReactNative. DexGuard currently provides its cutting-edge security solutions to the full-range of coding languages used for the Android platform, including JavaScript, Kotlin, Java and Native code (C/C++). Guardsquare’s technology answers to a growing global problem for enterprises rapidly undergoing digital transformation. As they quickly innovate and deploy more and more complex applications on increasingly powerful mobile devices, they often struggle with making these applications —running outside their corporate firewalls— secure. Still, for many companies and their mobile-centric custom